-
1Academic Journal
Authors: O. I. Kit, I. N. Turkin, D. A. Kharagezov, Yu. N. Lazutin, I. A. Leiman, A. V. Chubaryan, E. A. Mirzoyan, О. И. Кит, И. Н. Туркин, Д. А. Харагезов, Ю. Н. Лазутин, И. А. Лейман, А. В. Чубарян, Э. А. Мирзоян
Source: Siberian journal of oncology; Том 21, № 3 (2022); 143-150 ; Сибирский онкологический журнал; Том 21, № 3 (2022); 143-150 ; 2312-3168 ; 1814-4861 ; 10.21294/1814-4861-2022-21-3
Subject Terms: прогноз, multiple, synchronous, surgical treatment, multimodal therapy, prognosis, множественный, синхронный, хирургическое лечение, мультимодальная терапия
File Description: application/pdf
Relation: https://www.siboncoj.ru/jour/article/view/2172/997; Владимирова Л.Ю., Кит О.И., Шолохова Е.А. Роль гистологического и молекулярного анализа в выборе метода лечения немелкоклеточного рака легкого поздних стадий. Фарматека. 2012; 8(241): 9–22.; Romaszko A.M., Doboszyńska A. Multiple primary lung cancer: A literature review. Adv Clin Exp Med. 2018; 27(5): 725–30. doi:10.17219/ acem/68631.; Tanvetyanon T., Finley D.J., Fabian T., Riquet M., Voltolini L., Kocaturk C., Fulp W.J., Cerfolio R.J., Park B.J., Robinson L.A. Prognostic factors for survival after complete resections of synchronous lung cancers in multiple lobes: pooled analysis based on individual patient data. Ann Oncol. 2013; 24(4): 889–94. doi:10.1093/annonc/mds495.; Griffoen G.H., Lagerwaard F.J., Haasbeek C.J., Smit E.F., Slotman B.J., Senan S. Treatment of multiple primary lung cancers using stereotactic radiotherapy, either with or without surgery. Radiother Oncol. 2013; 107(3): 403–8. doi:10.1016/j.radonc.2013.04.026.; Riquet M., Cazes A., Pfeuty K., Ngabou U.D., Foucault C., Dujon A., Banu E. Multiple lung cancers prognosis: what about histology? Ann Thorac Surg. 2008; 86(3): 921–6. doi:10.1016/j.athoracsur.2008.05.041.; Leyn P. De, Moons J., Vansteenkiste J., Verbeken E., Raemdonck D.V., Nafteux P., Decaluwe H., Lerut T. Survival after resection of synchronous bilateral lung cancer. Eur J Cardiothorac Surg. 2008; 34(6): 1215–22. doi:10.1016/j.ejcts.2008.07.069.; Yang H., Sun Y., Yao F., Yu K., Gu H., Han B., Zhao H. Surgical Therapy for Bilateral Multiple Primary Lung Cancer. Ann Thorac Surg. 2016; 101(3): 1145–52. doi:10.1016/j.athoracsur.2015.09.028.; Лазутин Ю.Н., Сергостьянц Г.З., Пыльцин С.П., Харитонова А.П., Лейман И.А. Способ лечения рака легкого. Патент РФ № 2554750. Заявл. 13.02.2014; Опубл. 27.06.2015.; Tanvetyanon T., Robinson L., Sommers K.E., Haura E., Kim J., Altiok S., Bepler G. Relationship between tumor size and survival among patients with resection of multiple synchronous lung cancers. J Thorac Oncol. 2010; 5(7): 1018–24. doi:10.1097/JTO.0b013e3181dd0fb0.; Voltolini L., Rapicetta C., Luzzi L., Ghiribelli C., Paladini P., Granato F., Gallazzi M., Gotti G. Surgical treatment of synchronous multiple lung cancer located in a diferent lobe or lung: high survival in node-negative subgroup. Eur J Cardiothorac Surg. 2010; 37(5): 1198–204. doi:10.1016/j.ejcts.2009.11.025.; Fabian T., Bryant A.S., Mouhlas A.L., Federico J.A., Cerfolio R.J. Survival after resection of synchronous non-small cell lung cancer. J Thorac Cardiovasc Surg. 2011; 142(3): 547–53. doi:10.1016/j. jtcvs.2011.03.035.; https://www.siboncoj.ru/jour/article/view/2172
-
2Academic Journal
Authors: K. M. Nyushko, V. M. Perepukhov, B. Ya. Alekseev, К. М. Нюшко, В. М. Перепухов, Б. Я. Алексеев
Source: Urology Herald; Том 9, № 4 (2021); 70-86 ; Вестник урологии; Том 9, № 4 (2021); 70-86 ; 2308-6424 ; 10.21886/2308-6424-2021-9-4
Subject Terms: безрецидивная выживаемость, combined treatment, multimodal therapy, oligometastatic prostate cancer, drug pathomorphosis, prognostic factors, relapse-free survival, комбинированное лечение, мультимодальная терапия, олигометастатический рак предстательной железы, лекарственный патоморфоз, факторы прогноза
File Description: application/pdf
Relation: https://www.urovest.ru/jour/article/view/497/351; Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomata-ram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249. DOI:10.3322/caac.21660.; Culp SH, Schellhammer PF, Williams MB. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur Urol. 2014;65(6):1058-66. DOI:10.1016/j.eururo.2013.11.012.; Патент РФ на изобретение № 2695348 C2/23.07.2019. Бюл. № 21. Устинова Т. В., Болотина Л. В., Нюшко К. М., Пайчадзе А. А., Крашенинников А. А., Хмелевский Е. В., Каприн А. Д., Алексеев Б. Я. Способ лечения больных с наличием метастазов в лимфатических узлах и олигометастазов в костях скелета при раке предстательной железы. Доступно по: https://elibrary.ru/download/elibrary_39272235_84874246.PDF Ссылка активна на 13.11.2021.; Buelens S, Poelaert F, Dhondt B, Fonteyne V, De Viss-chere P, Ost P, Verbeke S, Villeirs G, De Man K, Rottey S, Decaestecker K, Lumen N. Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: Comparing definitions of CHAARTED and LATITUDE trial. Urol Oncol. 2018;36(4):158.e13-158.e20. DOI:10.1016/j.urolonc.2017.12.009.; Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberg-er M, Kohli M, Plimack ER, Vogelzang NJ, Picus J, Cooney MM, Garcia JA, DiPaola RS, Sweeney CJ. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial. J Clin Oncol. 2018;36(11):1080-1087. DOI:10.1200/JCO.2017.75.3657.; Armstrong AJ, Szmulewitz RZ, Petrylak DP, Villers A, Azad A, Alcaraz A, Alekseev BY, Iguchi T, Shore ND, Rosbrook B, Sugg J, Baron B, Chen LF, Stenzl A. Phase 3 study of androgen deprivation therapy (ADT) with enzalutamide (ENZA) or placebo (PBO) in metastatic hormone-sensitive prostate cancer (mHSPC): The ARCHES trial. Journal of Clinical Oncology. 2019;37(7_suppl):687-687. DOI:10.1200/JCO.2019.37.7_suppl.687.; Davis ID, Martin AJ, Stockler MR, Begbie S, Chi KN, Chowdhury S, Coskinas X, Frydenberg M, Hague WE, Horvath LG, Joshua AM, Lawrence NJ, Marx G, McCaffrey J, McDermott R, McJannett M, North SA, Parnis F, Parulekar W, Pook DW, Reaume MN, Sandhu SK, Tan A, Tan TH, Thomson A, Tu E, Vera-Badillo F, Williams SG, Yip S, Zhang AY, Zielinski RR, Sweeney CJ; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group. Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. N Engl J Med. 2019;381(2):121-131. DOI:10.1056/NEJMoa1903835.; Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Theodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14(2):149-58. DOI:10.1016/S1470-2045(12)70560-0.; Sydes MR, Spears MR, Mason MD, Clarke NW, Dearnaley DP, de Bono JS, Attard G, Chowdhury S, Cross W, Gillessen S, Malik ZI, Jones R, Parker CC, Ritchie AWS, Russell JM, Millman R, Matheson D, Amos C, Gilson C, Birtle A, Brock S, Capaldi L, Chakraborti P, Choudhury A, Evans L, Ford D, Gale J, Gibbs S, Gilbert DC, Hughes R, McLaren D, Lester JF, Nikapota A, O'Sullivan J, Parikh O, Peedell C, Protheroe A, Rudman SM, Shaffer R, Sheehan D, Simms M, Srihari N, Strebel R, Sundar S, Tolan S, Tsang D, Varughese M, Wagstaff J, Parmar MKB, James ND; STAMPEDE Investigators. Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. Ann Oncol. 2018;29(5):1235-1248. DOI:10.1093/an-nonc/mdy072.; Wallis CJD, Klaassen Z, Bhindi B, Goldberg H, Chandrasekar T, Farrell AM, Boorjian SA, Kulkarni GS, Karnes RJ, Satkuna-sivam R. Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naive Prostate Cancer: A Systematic Review and Network Meta-analysis. Eur Urol. 2018;73(6):834-844. DOI:10.1016/j.eururo.2017.10.002.; Lussier YA, Khodarev NN, Regan K, Corbin K, Li H, Ganai S, Khan SA, Gnerlich JL, Darga TE, Fan H, Karpenko O, Paty PB, Posner MC, Chmura SJ, Hellman S, Ferguson MK, Weichselbaum RR. Oligo- and polymetastatic progression in lung metastasis (es) patients is associated with specific microRNAs. PLoS One. 2012;7(12): e50141. DOI:10.1371/journal.pone.0050141. Erratum in: PLoS One. 2013;8(6). DOI:10.1371/annotation/2489ae5e-3650-4897-8df6-3e974ca585c4.; Boeve LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, Delaere KPJ, Moorselaar RJAV, Verha-gen PCMS, van Andel G. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75(3):410-418. DOI:10.1016/j.eururo.2018.09.008.; Choudhury A, Chen RC, Henry A, Mistry H, Mitin T, Pinkawa M, Spratt DE. STAMPEDE: Is Radiation Therapy to the Primary a New Standard of Care in Men with Metastatic Prostate Cancer? Int J Radiat Oncol Biol Phys. 2019;104(1):33-35. DOI:10.1016/j.ijrobp.2018.12.040.; Zurita AJ, Pisters LL, Wang X, Troncoso P, Dieringer P, Ward JF, Davis JW, Pettaway CA, Logothetis CJ, Pagliaro LC. Integrating chemohormonal therapy and surgery in known or suspected lymph node metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2015;18(3):276-80. DOI:10.1038/pcan.2015.23.; Gandaglia G, Fossati N, Stabile A, Bandini M, Rigatti P, Montorsi F, Briganti A. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. Eur Urol. 2017;72(2):289-292. DOI:10.1016/j.eururo.2016.08.040.; Heidenreich A, Fossati N, Pfister D, Suardi N, Montorsi F, Shariat S, Grubmuller B, Gandaglia G, Briganti A, Karnes RJ. Cytoreductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. Eur Urol Oncol. 2018;1(1):46-53. DOI:10.1016/j.euo.2018.03.002.; Parikh NR, Huiza C, Patel JS, Tsai S, Kalpage N, Thein M, Pitcher S, Lee SP, Inouye WS, Jordan ML, Sanati H, Jafari L, Bennett CJ, Gin GE, Kishan AU, Reiter RE, Lewis M, Sadeghi A, Aronson WJ, Garraway IP, Rettig MB, Nickols NG. Systemic and tumor-directed therapy for oligometastatic prostate cancer: study protocol for a phase II trial for veterans with de novo oligometastatic disease. BMC Cancer. 2019;19(1):291. DOI:10.1186/s12885-019-5496-5.; Mathieu R, Korn SM, Bensalah K, Kramer G, Shariat SF. Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense? World J Urol. 2017;35(4):567-577. DOI:10.1007/s00345-016-1906-3.; Marenco J, Sooriakumaran P. Current concepts in oligometastatic prostate cancer: Is there a role for radical prostatectomy? Arch Esp Urol. 2019;72(2):174-181. PMID: 30855019.; Джабаров Ф. Р., Альникин А. Б., Толмачев В. Г. Олигометастатический рак предстательной железы: диагностика и предварительные результаты лучевого лечения. Вестник урологии. 2020;8(2):55-66. DOI:10.21886/23086424-2020-8-2-55-66.; https://www.urovest.ru/jour/article/view/497